Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
62,105.04 +2,736.58 (+4.61%) CMC Crypto 200
1,340.82 +63.84 (+5.00%)
Organovo Holdings, Inc. (ONVO)
| Previous close | 0.9504 |
| Open | 0.9500 |
| Bid | 0.8944 x 100 |
| Ask | 1.1900 x 100 |
| Day's range | 0.9500 - 1.1700 |
| 52-week range | 0.8900 - 2.0500 |
| Volume | |
| Avg. volume | 1,033,958 |
| Market cap | 11.733M |
| Beta (5Y monthly) | 0.90 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.1600 |
| Earnings date | 11 Jul 2024 - 15 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.55 |
GlobeNewswireOrganovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today released the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314 for the treatment of metabolic function-associated steatohepatitis (MASH). St
Insider MonkeyTop 15 3D Printing Companies in the US
In this article, we will take a look at the top 15 3D printing companies in the US. If you want to skip our detailed analysis, you can go directly to Top 5 3D Printing Companies in the US. Recent Trends in 3D Printing According to a report by Grand View Research, the global 3D […]
Simply Wall St.Organovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Organovo Holdings ( NASDAQ:ONVO ) Third Quarter 2024 Results Key Financial Results Net loss: US$3.60m (loss widened by...
